<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135628</url>
  </required_header>
  <id_info>
    <org_study_id>GAS-83-09/10-1</org_study_id>
    <nct_id>NCT01135628</nct_id>
  </id_info>
  <brief_title>Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy</brief_title>
  <official_title>Hyperproteic and Fiber-rich Diet Plus Probiotics (Lactobacillus Reuteri) and Nitazoxanide in the Treatment of Minimal Hepatic Encephalopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic encephalopathy is a serious complication of cirrhosis which relays under the burden&#xD;
      of diseases with therapeutical difficulties for its given morbidity and mortality and the&#xD;
      high recurrence it poses. Its treatment remains a challenge for most of the cases. Even more,&#xD;
      minimal hepatic encephalopathy is an entity that has an additional morbidity for it being a&#xD;
      subclinical entity. As so, the investigators propose an auxiliary treatment for the&#xD;
      management of such patients with minimal hepatic encephalopathy, using a specific diet&#xD;
      consisting on hyperproteic and fibre-rich foods along with two independent interventions,&#xD;
      whether a probiotic, lactobacillus reuteri, or a drug, nitozoxanide, so to diminish the rate&#xD;
      of progression to any clinical stage of hepatic encephalopathy and to revert minimal hepatic&#xD;
      encephalopathy itself to none hepatic encephalopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reverse minimal hepatic encephalopathy</measure>
    <time_frame>3 months</time_frame>
    <description>Reverse minimal hepatic encephalopathy to none evidence of hepatic encephalopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reverse minimal hepatic encephalopathy</measure>
    <time_frame>6 months</time_frame>
    <description>Reverse minimal hepatic encephalopathy to none evidence of clinical hepatic encephalopathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of progression</measure>
    <time_frame>3 months</time_frame>
    <description>Prevention of progression from minimal hepatic encephalopathy to any clinical stage of West Haven score of hepatic encephalopathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention of progression</measure>
    <time_frame>6 months</time_frame>
    <description>Prevention of progression from minimal hepatic encephalopathy to any clinical stage of West Haven score of hepatic encephalopathy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <condition>Minimal Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>MHE and diet plus lactobacillus reuteri</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and lactobacillus reuteri.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MHE and diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MHE and diet plus nitazoxanide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and nitazoxanide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Auxiliary Treatment</intervention_name>
    <description>Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months</description>
    <arm_group_label>MHE and diet plus lactobacillus reuteri</arm_group_label>
    <other_name>Biogaia</other_name>
    <other_name>Probiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hyperproteic and fiber-rich diet</intervention_name>
    <description>Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet</description>
    <arm_group_label>MHE and diet</arm_group_label>
    <arm_group_label>MHE and diet plus lactobacillus reuteri</arm_group_label>
    <arm_group_label>MHE and diet plus nitazoxanide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide tablets 400 mg, bid, orally for 6 months</description>
    <arm_group_label>MHE and diet plus nitazoxanide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatic Cirrhosis&#xD;
&#xD;
          -  Minimal hepatic Encephalopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Personal history of surgery in the last 4 weeks&#xD;
&#xD;
          -  Use of neuropsychiatric drugs&#xD;
&#xD;
          -  Neuropsychiatric disorders (Schizophrenia, bipolar disorder, major depression,&#xD;
             dementia and Attention-deficit hyperactivity disorder)&#xD;
&#xD;
          -  Thyroid disorders without replacement therapy&#xD;
&#xD;
          -  Hepatic or renal transplant&#xD;
&#xD;
          -  Alcoholism with active ingest of alcohol in the last 6 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Labour turn-overs&#xD;
&#xD;
          -  Spontaneous bacterial Peritonitis&#xD;
&#xD;
          -  Personal history of hepatocellular carcinoma&#xD;
&#xD;
          -  Placement of transjugular intrahepatic portosystemic shunt&#xD;
&#xD;
          -  Use of a probiotic in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo Torre-Delgadillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas de Nutricion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>ALDO TORRE DELGADILLO</investigator_full_name>
    <investigator_title>M.D. M.Sc</investigator_title>
  </responsible_party>
  <keyword>Hepatic cirrhosis</keyword>
  <keyword>Minimal hepatic encephalopathy</keyword>
  <keyword>Hyperproteic and fiber-rich diet</keyword>
  <keyword>Lactobacillus reuteri</keyword>
  <keyword>Psychometric Hepatic Encephalopathy Score (PHES)</keyword>
  <keyword>Critical Flicker Frequency (CFF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

